Suppression of growth of H-69 small cell lung carcinoma by antagonists of growth hormone releasing hormone and bombesin is associated with an inhibition of protein kinase C signaling

Celia A. Kanashiro, Andrew V Schally, Marta Zarandi, Brian D. Hammann, Jozsef L. Varga

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

We investigated the effects of antagonists of growth hormone-releasing hormone (GHRH) alone and in combination with bombesin/gastrin-releasing peptide (BN/GRP) antagonist RC-3940-11 on the growth of H-69 human small cell lung carcinoma (SCLC) xenografted into nude mice. Since the activation of the signaling pathways involving protein kinase C (PKC) and the subsequent steps involving mitogen-activated protein kinase (MAPK) and c-fos and c-jun oncogenes are known to be important mechanisms implicated in cellular growth, we investigated how the blockade of tumoral GHRI-1 receptor splice variants and BN/GRP receptors by these antagonists could interfere with these intracellular signaling pathways. Treatment with GHRH antagonists JV-1-65 or MZ-J-7-110 for 4 weeks significantly (p<0.05) decreased the tumor volume by 22.7 ± 3.0% and 36.7 ±3.6%, respectively, as compared to controls. A larger decrease in tumor volume of 73.0 ± 9.5% (p<0.01) was produced by BN/GRP antagonist RC-3940-11 and its combination with JV-1-65 caused the greatest tumor reduction of 91.0 ±9.8% (p<0.01) vs. controls. H-69 SCLC tumors expressed α-, β11-, δ- and η-PKC isoforms. Antagonists of GHRH and BN/GRP decreased significantly (p<0.05) the expression of β11- and δ-, but not of α- and η-PKC isoforms. They also inhibited MAPK levels, the effects being significant (p<0.05) in the groups that received BN/GRP antagonist. In addition, expression of c-fos and c-jun mRNA was reduced after combined treatment with JV-1-65 and RC-3940-11. The proliferation of H-69 SCLC cells "in vitro" was also significantly inhibited after incubation of cells with GHRH antagonist, PKC inhibitors or MAPK inhibitor. These findings suggest that the anti-proliferative effects of antagonists of GHRH and BN/GRP on H69-SCLC involve an inhibition of the signaling pathways of specific PKC isoforms, HAPK and c-fos and c-jun oncogenes.

Original languageEnglish
Pages (from-to)570-576
Number of pages7
JournalInternational Journal of Cancer
Volume112
Issue number4
DOIs
StatePublished - Nov 20 2004
Externally publishedYes

Fingerprint

Bombesin
Growth Hormone-Releasing Hormone
Gastrin-Releasing Peptide
Small Cell Lung Carcinoma
Protein Kinase C
Growth
Mitogen-Activated Protein Kinases
jun Genes
Hormone Antagonists
Protein Isoforms
Protein Kinase Inhibitors
Tumor Burden
Bombesin Receptors
Protein C Inhibitor
Nude Mice
Neoplasms
Messenger RNA

Keywords

  • Bombesin/GRP antagonist
  • Cancer therapy
  • GHRH antagonists
  • Protein kinase C

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Suppression of growth of H-69 small cell lung carcinoma by antagonists of growth hormone releasing hormone and bombesin is associated with an inhibition of protein kinase C signaling. / Kanashiro, Celia A.; Schally, Andrew V; Zarandi, Marta; Hammann, Brian D.; Varga, Jozsef L.

In: International Journal of Cancer, Vol. 112, No. 4, 20.11.2004, p. 570-576.

Research output: Contribution to journalArticle

@article{e21095f35cc545a08505fd186ff43668,
title = "Suppression of growth of H-69 small cell lung carcinoma by antagonists of growth hormone releasing hormone and bombesin is associated with an inhibition of protein kinase C signaling",
abstract = "We investigated the effects of antagonists of growth hormone-releasing hormone (GHRH) alone and in combination with bombesin/gastrin-releasing peptide (BN/GRP) antagonist RC-3940-11 on the growth of H-69 human small cell lung carcinoma (SCLC) xenografted into nude mice. Since the activation of the signaling pathways involving protein kinase C (PKC) and the subsequent steps involving mitogen-activated protein kinase (MAPK) and c-fos and c-jun oncogenes are known to be important mechanisms implicated in cellular growth, we investigated how the blockade of tumoral GHRI-1 receptor splice variants and BN/GRP receptors by these antagonists could interfere with these intracellular signaling pathways. Treatment with GHRH antagonists JV-1-65 or MZ-J-7-110 for 4 weeks significantly (p<0.05) decreased the tumor volume by 22.7 ± 3.0{\%} and 36.7 ±3.6{\%}, respectively, as compared to controls. A larger decrease in tumor volume of 73.0 ± 9.5{\%} (p<0.01) was produced by BN/GRP antagonist RC-3940-11 and its combination with JV-1-65 caused the greatest tumor reduction of 91.0 ±9.8{\%} (p<0.01) vs. controls. H-69 SCLC tumors expressed α-, β11-, δ- and η-PKC isoforms. Antagonists of GHRH and BN/GRP decreased significantly (p<0.05) the expression of β11- and δ-, but not of α- and η-PKC isoforms. They also inhibited MAPK levels, the effects being significant (p<0.05) in the groups that received BN/GRP antagonist. In addition, expression of c-fos and c-jun mRNA was reduced after combined treatment with JV-1-65 and RC-3940-11. The proliferation of H-69 SCLC cells {"}in vitro{"} was also significantly inhibited after incubation of cells with GHRH antagonist, PKC inhibitors or MAPK inhibitor. These findings suggest that the anti-proliferative effects of antagonists of GHRH and BN/GRP on H69-SCLC involve an inhibition of the signaling pathways of specific PKC isoforms, HAPK and c-fos and c-jun oncogenes.",
keywords = "Bombesin/GRP antagonist, Cancer therapy, GHRH antagonists, Protein kinase C",
author = "Kanashiro, {Celia A.} and Schally, {Andrew V} and Marta Zarandi and Hammann, {Brian D.} and Varga, {Jozsef L.}",
year = "2004",
month = "11",
day = "20",
doi = "10.1002/ijc.20437",
language = "English",
volume = "112",
pages = "570--576",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Suppression of growth of H-69 small cell lung carcinoma by antagonists of growth hormone releasing hormone and bombesin is associated with an inhibition of protein kinase C signaling

AU - Kanashiro, Celia A.

AU - Schally, Andrew V

AU - Zarandi, Marta

AU - Hammann, Brian D.

AU - Varga, Jozsef L.

PY - 2004/11/20

Y1 - 2004/11/20

N2 - We investigated the effects of antagonists of growth hormone-releasing hormone (GHRH) alone and in combination with bombesin/gastrin-releasing peptide (BN/GRP) antagonist RC-3940-11 on the growth of H-69 human small cell lung carcinoma (SCLC) xenografted into nude mice. Since the activation of the signaling pathways involving protein kinase C (PKC) and the subsequent steps involving mitogen-activated protein kinase (MAPK) and c-fos and c-jun oncogenes are known to be important mechanisms implicated in cellular growth, we investigated how the blockade of tumoral GHRI-1 receptor splice variants and BN/GRP receptors by these antagonists could interfere with these intracellular signaling pathways. Treatment with GHRH antagonists JV-1-65 or MZ-J-7-110 for 4 weeks significantly (p<0.05) decreased the tumor volume by 22.7 ± 3.0% and 36.7 ±3.6%, respectively, as compared to controls. A larger decrease in tumor volume of 73.0 ± 9.5% (p<0.01) was produced by BN/GRP antagonist RC-3940-11 and its combination with JV-1-65 caused the greatest tumor reduction of 91.0 ±9.8% (p<0.01) vs. controls. H-69 SCLC tumors expressed α-, β11-, δ- and η-PKC isoforms. Antagonists of GHRH and BN/GRP decreased significantly (p<0.05) the expression of β11- and δ-, but not of α- and η-PKC isoforms. They also inhibited MAPK levels, the effects being significant (p<0.05) in the groups that received BN/GRP antagonist. In addition, expression of c-fos and c-jun mRNA was reduced after combined treatment with JV-1-65 and RC-3940-11. The proliferation of H-69 SCLC cells "in vitro" was also significantly inhibited after incubation of cells with GHRH antagonist, PKC inhibitors or MAPK inhibitor. These findings suggest that the anti-proliferative effects of antagonists of GHRH and BN/GRP on H69-SCLC involve an inhibition of the signaling pathways of specific PKC isoforms, HAPK and c-fos and c-jun oncogenes.

AB - We investigated the effects of antagonists of growth hormone-releasing hormone (GHRH) alone and in combination with bombesin/gastrin-releasing peptide (BN/GRP) antagonist RC-3940-11 on the growth of H-69 human small cell lung carcinoma (SCLC) xenografted into nude mice. Since the activation of the signaling pathways involving protein kinase C (PKC) and the subsequent steps involving mitogen-activated protein kinase (MAPK) and c-fos and c-jun oncogenes are known to be important mechanisms implicated in cellular growth, we investigated how the blockade of tumoral GHRI-1 receptor splice variants and BN/GRP receptors by these antagonists could interfere with these intracellular signaling pathways. Treatment with GHRH antagonists JV-1-65 or MZ-J-7-110 for 4 weeks significantly (p<0.05) decreased the tumor volume by 22.7 ± 3.0% and 36.7 ±3.6%, respectively, as compared to controls. A larger decrease in tumor volume of 73.0 ± 9.5% (p<0.01) was produced by BN/GRP antagonist RC-3940-11 and its combination with JV-1-65 caused the greatest tumor reduction of 91.0 ±9.8% (p<0.01) vs. controls. H-69 SCLC tumors expressed α-, β11-, δ- and η-PKC isoforms. Antagonists of GHRH and BN/GRP decreased significantly (p<0.05) the expression of β11- and δ-, but not of α- and η-PKC isoforms. They also inhibited MAPK levels, the effects being significant (p<0.05) in the groups that received BN/GRP antagonist. In addition, expression of c-fos and c-jun mRNA was reduced after combined treatment with JV-1-65 and RC-3940-11. The proliferation of H-69 SCLC cells "in vitro" was also significantly inhibited after incubation of cells with GHRH antagonist, PKC inhibitors or MAPK inhibitor. These findings suggest that the anti-proliferative effects of antagonists of GHRH and BN/GRP on H69-SCLC involve an inhibition of the signaling pathways of specific PKC isoforms, HAPK and c-fos and c-jun oncogenes.

KW - Bombesin/GRP antagonist

KW - Cancer therapy

KW - GHRH antagonists

KW - Protein kinase C

UR - http://www.scopus.com/inward/record.url?scp=7044235571&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7044235571&partnerID=8YFLogxK

U2 - 10.1002/ijc.20437

DO - 10.1002/ijc.20437

M3 - Article

C2 - 15382037

AN - SCOPUS:7044235571

VL - 112

SP - 570

EP - 576

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 4

ER -